From the Journals

Low-Dose Rivaroxaban Did Not Reduce LV Thrombus After Anterior STEMI

Adding low-dose rivaroxaban to dual antiplatelet therapy following anterior myocardial infarction did not reduce cardiac MRI–detected left ventricular thrombus at 1 month and increased minor bleeding in a 560-patient randomized trial.

Share

  • 1

    APERITIF trial assessed rivaroxaban with dual antiplatelet therapy.

  • 2

    Conducted at 29 French centers.

  • 3

    No significant reduction in left ventricular thrombus rates.

  • 4

    14% in rivaroxaban group vs 17% in control.

  • 5

    Increased bleeding events with rivaroxaban.

  • 6

    Open-label design and fewer thrombus events noted as limitations.

  • 7

    Major adverse cardiovascular events were rare.

  • 8

    Funded by the French Ministry of Health.

Original Source(s)

Low-Dose Rivaroxaban Did Not Reduce LV Thrombus After Anterior STEMI

Adding low-dose rivaroxaban to dual antiplatelet therapy following anterior myocardial infarction did not reduce cardiac MRI–detected left ventricular thrombus at 1 month and increased minor bleeding in a 560-patient randomized trial.

  • by Doug Brunk

  • March 4, 2026

  • 3 min

Related Content

Quality of Life in Cardiac Arrest Recovery

Post–cardiac arrest care is increasingly structured around survivorship, with standardized patient-reported assessments supporting multidisciplinary follow-up.

Back on the Golf Course in Three Weeks After Minimally Invasive Bypass Surgery

Like many individuals with heart disease, Mr. Zells had no idea there was a serious issue with his heart. “I didn’t know I had any problem at all,” he recalls.

  • by

  • February 11, 2026

  • 9 min
AHA Issues Statement on ACS in Young Women

Knowledge and outcome gaps in premenopausal women with acute coronary syndrome demand tailored approaches to diagnosis and care